Hormonal
GLP-1 receptor agonist therapy improves tear production and tear film stability in patients with type 2 diabetes compared to non-GLP-1 RA therapies.
If you have Type 2 Diabetes and are considering or using GLP-1 RAs (like semaglutide or dulaglutide), this research suggests these medications might actually help keep your eyes moist and stable compared to other diabetes drugs. While this doesn't replace standard dry eye treatments, it is a potential benefit to discuss with your doctor, especially if you suffer from dry eye symptoms.
Patients receiving GLP-1 RAs demonstrated significantly higher Schirmer I test values (median 15 mm, range 1–33) compared to non-GLP-1 RA users (median 7.5 mm, range 0–40; p = 0.016). TBUT was also significantly longer in the GLP-1 RA group (median 10 sec, range 6.7–17) versus controls (median 5.85 sec, range 1–11; p < 0.01).
Why this rating
Retrospective case-control study with small sample size (n=35) and potential confounders.
Source
GLP-1R Agonists Improve Ocular Surface Parameters in Type 2 Diabetes Mellitus
Giovanni Ottonelli et al. · Clinical ophthalmology · 2025
DOI 10.2147/opth.s547776
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →